Breaking News Bar

Business News and Information

$1.5B deal: AstraZeneca sells U.S. rights to respiratory medicine

AstraZeneca's deal to sell the U.S. rights to Synagis to a Swedish biopharmaceutical company is expected to be finalized early next year.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear